| Company/Division name | RayzeBio |
| Parent company | Bristol Myers Squibb |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 160 |
| City reshored to: | Indianapolis |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | radiopharmaceutical treatments |
| What domestic positive factors made reshoring more attractive? | Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training |
